Seroprevalence of SARS-CoV-2 in slums and non-slums of Mumbai, India, during June 29-July 19, 2020
Preprint
Abstract
Objective: Estimate seroprevalence in representative samples from slum and non-slum communities in Mumbai, India, a mega-city in a low or middle-income country and test if prevalence is different in slums. Design: After geographically-spaced community sampling of households, one individual per household was tested for IgG antibodies to SARS-CoV-2 N-protein in a two-week interval. Setting: Slum and non-slum communities in three wards, one each from the three main zones of Mumbai. Participants: Individuals over age 12 who consent to and have no contraindications to venipuncture were eligible. 6,904 participants (4,202 from slums and 2,702 from non-slums) were tested. Main outcome measures: The primary outcomes were the positive test rate for IgG antibodies to the SARS-CoV-2 N-protein by demographic group (age and gender) and location (slums and non-slums). The secondary outcome is seroprevalence at slum and non-slum levels. Sera was tested via chemiluminescence (CLIA) using Abbott Diagnostics Architect TM N-protein based test. Seroprevalence was calculated using weights to match the population distribution by age and gender and accounting for imperfect sensitivity and specificity of the test. Results: The positive test rate was 54.1% (95% CI: 52.7 to 55.6) and 16.1% (95% CI: 14.9 to 17.4) in slums and non-slums, respectively, a difference of 38 percentage points (P < 0.001). Accounting for imperfect accuracy of tests (e.g., sensitivity, 0.90; specificity 1.00), seroprevalence was as high as 58.4% (95% CI: 56.8 to 59.9) and 17.3% (95% CI: 16 to 18.7) in slums and non-slums, respectively. Conclusions: The high seroprevalence in slums implies a moderate infection fatality rate. The stark difference in seroprevalence across slums and non-slums has implications for the efficacy of social distancing, the level of herd immunity, and equity. It underlines the importance of geographic specificity and urban structure in modeling SARS-CoV-2.Keywords
All Related Versions
- Published version: The Lancet Global Health, 9 (2), e110.
This publication has 11 references indexed in Scilit:
- A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2Science, 2020
- Seroprevalence of SARS-CoV-2 in Niger State: A Pilot Cross Sectional StudymedRxiv, 2020
- Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological studyThe Lancet, 2020
- Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, IdahoJournal of Clinical Microbiology, 2020
- Adaptive Control of COVID-19 Outbreaks in India: Local, Gradual, and Trigger-based Exit Paths from Lockdown2020
- Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020JAMA, 2020
- Spread of SARS-CoV-2 in the Icelandic PopulationNew England Journal of Medicine, 2020
- Seroprevalence of COVID-19 virus infection in Guilan province, IranmedRxiv, 2020
- The similar size of slumsHabitat International, 2018
- ESTIMATING PREVALENCE FROM THE RESULTS OF A SCREENING TESTAmerican Journal of Epidemiology, 1978